Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 39, 2024 - Issue 1
Submit an article Journal homepage
1,510
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer

Lijie Simaa Department of Hematology and Oncology, The Affiliated Shaoyang Hospital, Hengyang Medical School, University of South China (Shaoyang Central Hospital), Shaoyang, ChinaView further author information
,
Zhongyuan Wangb Department of Pharmacy, Guizhou Provincial People’s Hospital, Guiyang, ChinaView further author information
,
Ling Yuc Department of Pharmacy, Guiyang Healthcare Vocational University, Guiyang, ChinaView further author information
,
Youli Houd Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, ChinaView further author information
,
Dongsheng Zhaod Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, ChinaView further author information
,
Bilan Luod Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, ChinaView further author information
,
Weike Liaod Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, ChinaView further author information
&
Xinfu Liua Department of Hematology and Oncology, The Affiliated Shaoyang Hospital, Hengyang Medical School, University of South China (Shaoyang Central Hospital), Shaoyang, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2286435 | Received 16 Jun 2023, Accepted 17 Nov 2023, Published online: 11 Dec 2023

References

  • Gao Q, Liang W-W, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao W-W, Reynolds SM, Wyczalkowski MA, Yao L, et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018;23(1):227–238.e3.
  • Wang MN, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–1356.
  • Colombino M, Paliogiannis P, Cossu A, Santeufemia DA, Sini MC, Casula M, Palomba G, Manca A, Pisano M, Doneddu V, et al. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC Pulm Med. 2019;19(1):209.
  • Fu J, Su X, Li Z, Deng L, Liu X, Feng X, Peng J. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene. 2021;40(28):4625–4651.
  • Zambelli A, Biamonti G, Amato A. HGF/c-Met signalling in the tumor microenvironment. Adv Exp Med Biol. 2021;1270:31–44.
  • Uchikawa E, Chen Z, Xiao G-Y, Zhang X, Bai X-C. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(1):4074.
  • Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45.
  • Liu XD, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010;16(1):37–45.
  • Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem. 2014;57(11):4427–4453.
  • Wang CF, Lu XY. Targeting MET: discovery of small molecule inhibitors as non-small cell lung cancer therapy. J Med Chem. 2023;66(12):7670–7697.
  • Parikh PK, Ghate MD. Recent advances in the discovery of small molecule c-Met kinase inhibitors. Eur J Med Chem. 2018;143:1103–1138.
  • https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
  • Markham A. Savolitinib: first approval. Drugs. 2021;81(14):1665–1670.
  • Huang C, Zou Q, Liu H, Qiu B, Li Q, Lin Y, Liang Y. Management of non-small cell lung cancer patients with MET Exon 14 skipping mutations. Curr Treat Options Oncol. 2020;21(4):33.
  • Zhou S, Liao H, He C, Dou Y, Jiang M, Ren L, Zhao Y, Gong P. Design, synthesis and structure–activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents. Eur J Med Chem. 2014;83:581–593.
  • Liao W, Hu G, Guo Z, Sun D, Zhang L, Bu Y, Li Y, Liu Y, Gong P. Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors. Bioorg Med Chem. 2015;23(15):4410–4422.
  • Liao WK, Tang L, Wang ZY, et al. 2,4-disubstituted pyridine compound and its application. CN116283920A.
  • Qi B, Mi B, Zhai X, Xu Z, Zhang X, Tian Z, Gong P. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors. Bioorg Med Chem. 2013;21(17):5246–5260.
  • Liao W, Wang Z, Han Y, Qi Y, Liu J, Xie J, Tian Y, Lei Q, Chen R, Sun M, et al. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity. Eur J Med Chem. 2020;197:112309.
  • Chen R, Wang ZY, Sima LJ, et al. Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K α inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):2155638.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.